Literature DB >> 18955515

Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.

Nicole Ritz1, Marc Tebruegge, Tom G Connell, Aina Sievers, Roy Robins-Browne, Nigel Curtis.   

Abstract

Mycobacterium bovis BCG is one of the most commonly administered vaccines. Complications, including disseminated BCG disease, are rare but increasingly reported in immunodeficient children. There is growing recognition of the importance of differences between BCG vaccine strains. We determined the susceptibilities of five genetically distinct BCG vaccine strains to 12 antituberculous drugs.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18955515      PMCID： PMC2612166          DOI： 10.1128/AAC.01302-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  A COMPARATIVE STUDY OF THE SUSCEPTIBILITY TO ETHIONAMIDE, THIOSEMICARBAZONE, AND ISONIAZID OF TUBERCLE BACILLI FROM PATIENTS NEVER TREATED WITH ETHIONAMIDE OR THIOSEMICARBAZONE.

Authors:  T T HOK
Journal:  Am Rev Respir Dis       Date:  1964-09

Review 2.  Second IUATLD study on complications induced by intradermal BCG-vaccination.

Authors:  A Lotte; O Wasz-Hockert; N Poisson; H Engbaek; H Landmann; U Quast; B Andrasofszky; L Lugosi; I Vadasz; P Mihailescu
Journal:  Bull Int Union Tuberc Lung Dis       Date:  1988-06

3.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

4.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

5.  Comparative genomics of BCG vaccines by whole-genome DNA microarray.

Authors:  M A Behr; M A Wilson; W P Gill; H Salamon; G K Schoolnik; S Rane; P M Small
Journal:  Science       Date:  1999-05-28       Impact factor: 47.728

6.  Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children.

Authors:  A C Hesseling; H Rabie; B J Marais; M Manders; M Lips; H S Schaaf; R P Gie; M F Cotton; P D van Helden; R M Warren; N Beyers
Journal:  Clin Infect Dis       Date:  2006-01-11       Impact factor: 9.079

7.  In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children.

Authors:  Anneke C Hesseling; Hendrik S Schaaf; Thomas Victor; Nulda Beyers; Ben J Marais; Mark F Cotton; Ian Wiid; Robert P Gie; Paul van Helden; Robin M Warren
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

9.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.

Authors:  A Banerjee; E Dubnau; A Quemard; V Balasubramanian; K S Um; T Wilson; D Collins; G de Lisle; W R Jacobs
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

10.  Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex.

Authors:  Karolína Buriánková; Florence Doucet-Populaire; Olivier Dorson; Anne Gondran; Jean-Claude Ghnassia; Jaroslav Weiser; Jean-Luc Pernodet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
View more
  29 in total

1.  Chest wall abscess due to Mycobacterium bovis BCG after intravesical BCG therapy.

Authors:  Hajime Kanamori; Katsuhiko Isogami; Takashi Hatakeyama; Hiroo Saito; Kazuyoshi Shimada; Bine Uchiyama; Noboru Aso; Mitsuo Kaku
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

Review 2.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

3.  Thr270Ile in embC (Rv3793) is not a marker for ethambutol resistance in the Mycobacterium tuberculosis complex.

Authors:  Claudio U Köser; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2011-04       Impact factor: 5.191

Review 4.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

5.  Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.

Authors:  H Rabie; A Violari; T Duong; S A Madhi; D Josipovic; S Innes; E Dobbels; E Lazarus; R Panchia; A G Babiker; D M Gibb; M F Cotton
Journal:  Int J Tuberc Lung Dis       Date:  2011-09       Impact factor: 2.373

6.  Molecular Mechanisms of Intrinsic Streptomycin Resistance in Mycobacterium abscessus.

Authors:  Michael Dal Molin; Myriam Gut; Anna Rominski; Klara Haldimann; Katja Becker; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Ethambutol Is Cleared by a Contemporary High-Flux Hemodialyzer, and Drug Monitoring Ensures Safety and Therapeutic Effect.

Authors:  Rusheng Chew; Sarah Jongbloed; Dev Jegatheesan; Helen Healy; Kim Ta; Jacobus Ungerer; Brett McWhinney; Peter Donovan; Marion L Woods
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Clinical and laboratory observation of Bacillus Calmette-Guérin infections.

Authors:  Shuihua Lu; Tao Li; Xiuhong Xi; Qingguo Chen; Xuhui Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Accurate Identification of Closely Related Mycobacterium tuberculosis Complex Species by High Resolution Tandem Mass Spectrometry.

Authors:  Amol O Bajaj; Suraj Saraswat; Juha E A Knuuttila; Joanna Freeke; J Benjamin Stielow; Adam P Barker
Journal:  Front Cell Infect Microbiol       Date:  2021-06-22       Impact factor: 5.293

10.  Admixed phylogenetic distribution of drug resistant Mycobacterium tuberculosis in Saudi Arabia.

Authors:  Bright Varghese; Philip Supply; Caroline Allix-Béguec; Mohammed Shoukri; Ruba Al-Omari; Mais Herbawi; Sahal Al-Hajoj
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.